Media stories about Agile Therapeutics (NASDAQ:AGRX) have been trending somewhat positive this week, Accern Sentiment reports. The research group scores the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Agile Therapeutics earned a daily sentiment score of 0.23 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 48.5370935788406 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment’s analysis:
- Is Agile Therapeutics Inc’s (NASDAQ:AGRX) Balance Sheet A Threat To Its Future? (finance.yahoo.com)
- Analysts’ Suggestions to Watch – Agile Therapeutics, Inc. (NASDAQ: AGRX) – The Investor Guide (wallstreetnews24.com)
- Agile Therapeutics (AGRX) Receives “Buy” Rating from Noble Financial (americanbankingnews.com)
- Agile Therapeutics Inc (AGRX) Forecasted to Earn Q1 2018 Earnings of ($0.19) Per Share (americanbankingnews.com)
- Agile Therapeutics Reports Fourth Quarter and Full Year 2017 … – Markets Insider (markets.businessinsider.com)
AGRX has been the subject of several analyst reports. HC Wainwright set a $8.00 price target on shares of Agile Therapeutics and gave the stock a “buy” rating in a report on Friday, December 22nd. Janney Montgomery Scott cut shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Friday, December 22nd. Cantor Fitzgerald reiterated a “buy” rating and issued a $5.00 price target on shares of Agile Therapeutics in a research report on Friday, December 22nd. Noble Financial reiterated a “buy” rating on shares of Agile Therapeutics in a research report on Friday, December 22nd. Finally, William Blair lowered shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a research report on Tuesday, December 26th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the stock. Agile Therapeutics presently has an average rating of “Hold” and a consensus target price of $9.00.
TRADEMARK VIOLATION NOTICE: “Agile Therapeutics (NASDAQ:AGRX) Getting Somewhat Positive Media Coverage, Study Shows” was originally reported by BBNS and is owned by of BBNS. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright and trademark law. The correct version of this piece can be viewed at https://baseballnewssource.com/2018/03/21/agile-therapeutics-agrx-receives-media-impact-rating-of-0-23/2030524.html.
About Agile Therapeutics
Agile Therapeutics, Inc is a women’s health specialty pharmaceutical company. The Company is focused in the development and commercialization of prescription contraceptive products. The Company has developed a transdermal patch technology, called Skinfusion. The Company’s lead product candidate is Twirla, also known as AG200-15, is a combined hormonal contraceptive (CHC) patch.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.